Showing results (11-20 of 218) with videos related to
Sort By:
Pageof 22
Pharmacoeconomics|November 5, 2004
Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinenceDyfrig A Hughes, Dominique DuboisNature Reviews. Drug Discovery|January 1, 2013
Pharmacogenetic tests: the need for a level playing fieldMunir Pirmohamed, Dyfrig A HughesEuropean Journal of Clinical Pharmacology|September 29, 2020
What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristicsAbdullah Albassam, Dyfrig A HughesHealth Economics|September 11, 2012
Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great BritainWarren G Linley, Dyfrig A HughesPharmacoeconomics|September 9, 2024
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of BiasYankier Pijeira Perez, Dyfrig A HughesPharmacoeconomics|June 9, 2012
Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factorsWarren G Linley, Dyfrig A HughesPlos One|October 22, 2016
Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control StudyDyfrig A Hughes, Jannine Poletti-HughesJournal of Clinical Pharmacology|October 3, 2009
A systematic review and empirical analysis of the relation between dose and duration of drug actionDyfrig A Hughes, Jeffrey K AronsonCPT: Pharmacometrics & Systems Pharmacology|December 14, 2020
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial DesignDaniel Hill-McManus, Dyfrig A HughesBritish Journal of Clinical Pharmacology|August 19, 2010
Generic and therapeutic substitutions in the UK: are they a good thing?Martin G Duerden, Dyfrig A HughesPageof 22